Key Highlights
- TransMedics Group (NASDAQ:TMDX) was trading up 23.59% at USD 85.26 on Friday, November 6, 2026, the day after reporting third-quarter 2026 results and raising its Revenue outlook.
- Third-quarter revenue rose 41% to USD 203.0 million from USD 143.8 million, and 35% excluding the PAD Aviation acquisition, with service revenue up 60% to USD 89.6 million.
- Net income fell to USD 17.1 million from USD 24.3 million, or USD 0.46 a diluted share against USD 0.66, as operating expenses rose to USD 90.5 million.
- Full-year 2026 revenue guidance rose to USD 764 million to USD 774 million including PAD Aviation, and cash stood at USD 493.0 million on September 30, 2026.
Revenue Beat and Raised Outlook Overshadow Lower Profit
TransMedics Group (NASDAQ:TMDX) reported third-quarter results on November 5, 2026, with revenue of USD 203.0 million, up 41% from USD 143.8 million. Product revenue rose 29% to USD 113.4 million and service revenue rose 60% to USD 89.6 million. The company raised 2026 revenue guidance excluding PAD Aviation to USD 750 million to USD 760 million from USD 737 million to USD 757 million. Including about USD 14 million expected from PAD Aviation, the range is USD 764 million to USD 774 million. Shares were trading sharply higher the next day, which suggests investors weighed the growth and raised guide above the weaker earnings. Organic growth, which excludes the PAD Aviation acquisition, was 35% for the quarter.
Why Earnings Fell While Sales Climbed
Operating income rose 21% to USD 28.1 million, yet Operating Margin slipped 230 basis points to 13.9% as spending grew faster than sales. Research and Development jumped to USD 29.2 million from USD 15.3 million, and selling, general and administrative expense reached USD 61.3 million from USD 46.0 million. Gross margin was 58.5% versus 58.8%. Diluted Earnings per Share were USD 0.46 against USD 0.66, and adjusted earnings per share were USD 0.51 against USD 0.67. For nine months, revenue rose 27% to USD 566.9 million while Net Income fell to USD 39.1 million from USD 84.9 million. Stock-based compensation also climbed to USD 12.1 million from USD 8.7 million.
Pipeline Milestones, Cash and the Risk Ahead
The company reported completed enrollment in Part A of its ENHANCE Heart trial, an FDA-approved continued access protocol, IDE approvals for ENHANCE Heart Part B and the DENOVO Lung trial, and its first European transplant logistics tender win in Italy. It named Fernando Araujo chief financial officer. Cash was USD 493.0 million. On October 26 the stock was near USD 70.63 against a 52-week range of USD 60.11 to USD 156.00, so USD 85.26 is about 45% below the high (calculated). Risks include rising spending, trial outcomes, and a September law-firm investigation announcement, which is unproven. Whether margins recover as new programs mature is the open question for the next report.
Where Things Stand
The jump came because revenue growth and a higher full-year outlook outweighed a drop in profit. TransMedics Group (NASDAQ:TMDX) delivered 41% growth and raised guidance, while margins narrowed on heavier research and administrative costs. The stock remains well below its 52-week high, so the move recovers part of an earlier decline rather than setting a record. Next markers are fourth-quarter results, the pace of operating-expense growth, and trial updates in heart and lung programs.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...